Compare Annaly Capital Management, Inc. (NLY) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Annaly Capital Management, Inc. vs Pfizer Inc — how do they compare? Annaly Capital Management, Inc. trades at $18.41 (market cap $13.51B), while Pfizer Inc trades at $27.78 (market cap $159.59B). The key difference: Pfizer Inc is far larger — about 11.8× Annaly Capital Management, Inc.'s market cap, and Annaly Capital Management, Inc. pays the higher dividend (16.73%). Which is the better fit depends on your goals — on Pluang, investors hold Annaly Capital Management, Inc. for 92 Days and Pfizer Inc for 158 Days on average.
| NLY | PFE | |
|---|---|---|
Market Cap | $13.51B | $159.59B |
Volume | 18,617,936 | 30,937,010 |
Sector | Real Estate | Health |
52-Week High | $24.40 | $29.02 |
52-Week Low | $17.93 | $23.67 |
Typical Hold Time | 92 Days | 158 Days |
Enterprise Value | $135.54B | $211.09B |
Dividend Yield | 16.73% | 6.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NLY trades at $17.93, down 2.66% on the day, amid a bearish technical signal despite a low P/E of 4.33 and P/B of 0.89 suggesting undervaluation. The company has beaten EPS estimates for the last three quarters, with Q3 2026 results pending. Strong profitability metrics include a net income margin of 92.77% and ROE of 20.66%. Recent news highlights its high dividend yield near 15% and portfolio expansion, though the stock faces pressure from rising mortgage rates and a negative cash flow from investing activities of -$27.36 billion in 2025.
The outlook is mixed: attractive valuation and consistent earnings beats support upside to the $22.00 consensus price target, but high leverage (debt-to-asset ratio of 23.55 in 2025) and interest rate sensitivity pose significant risks. Investors are compensated with a robust dividend, yet the stock's recent decline reflects concerns over macroeconomic headwinds impacting mortgage REITs.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
